Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
NCT00379340Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Apr 2007
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Targeted Liposomes
- Countries
- 7
01
Overview
A Phase 3 trial of actinomycin D, vincristine sulfate liposome injection, pegylated liposomal doxorubicin, cyclophosphamide, etoposide in Wilms' tumor, sponsored by Children's Oncology Group. Started Apr 2007; status: completed.
02
Drugs
actinomycin Dvincristine sulfate liposome injectionpegylated liposomal doxorubicincyclophosphamideetoposide
03
Conditions
Wilms' tumor
Beyond the preview
Go deeper on NCT00379340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379340.